Barry Freedman, MD |
R01 DK071891 (NIH/NIDD)
09/01/2007-06/30/2012
Subclinical CVD in African American Type 2 Diabetes The long term objective of the African American Diabetes Heart Study is to locate and identify genes contributing to the inherited component of subclinical cardiovascular disease in African Americans with type 2 diabetes mellitus. Principal Investigator: Barry I. Freedman, M.D. |
1R01 DK084149 (NIH/NIDDK)
07/01/2009-06/30/2013
Natural History of MYH9-Associated Nephropathy This longitudinal study evaluates close relatives of African Americans with non-diabetic end-stage renal disease to detect second hits initiating nephropathy. Principal Investigator: Barry I. Freedman, M.D.
Co-Investigator: Michael Rocco, M.D. |
1R01 NS075107-01 (NIH)
06/1/2011-6/30/2016
Cerebrovascular disease and cognitive performance in African Americans This study has the goal of identifying the epidemiologic and genetic associations with cerebral white matter changes in African Americans with type 2 diabetes. Principal Investigator: Barry I. Freedman, M.D. |
2R01 DK070941-05 (NIH/NIDDK)
09/22/2011-04/30/2016
An integrative genomic approach to APOL1-associated nephropathy This study has the goal of identifying the mechanisms whereby APOL1 gene polymorphisms cause non-diabetic nephropathy in African Americans. Principal Investigator: Barry I. Freedman, M.D.
Co-Investigator: Mariana Murea, M.D. |
1R01 NS058700-01A1 (NIH)
04/1/2008-03/31/2013
Genetic Epidemiology of Cerebrovascular Disease and Cognition in Diabetes The goal of this study is to determine relationships between cognition and CVD and detect causative genes. Principal Investigator: Donald Bowden, Ph.D.
Co-Investigator: Barry Freedman, M.D. |
HHSN268200900040C (NIH/NHLBI)
09/30/2009-09/29/2018
Systolic Blood Pressure Intervention Trial (SPRINT) This trial will test the effects of intensive SBP lowering compared with standard lowering: a comparison of a SBP goal of <120 mmHg versus <140 mmHG for a SBP difference of 10-15 mm HG between two randomized groups. The primary endpoint is incident CVD events identified over a 5 year follow-up. Principal Investigator: David Reboussin, Ph.D.
Co-Investigator: Barry Freedman, M.D. |
5R01 HL092301 Bowden (NIH)
04/01/2010-1/31/2014
Whole Genome Association Analysis of the Diabetes Heart Study The study has the goal of identifying genes that contribute to cardiovascular disease in people with diabetes. Principal Investigator: Donald Bowden, Ph.D.
Co-Investigator: Barry Freedman, M.D. |
RO1DK090111-01 (NIH)
5/13/2011-11/30/2015
Mapping diabetic susceptibility by expression traits in African Americans This study has the goal of linking gene expression in adipose and muscle tissue with GWAS data in African Americans. Principal Investigator: S.K. Das, Ph.D.
Co-Investigator: Barry Freedman, M.D.
Co-Investigator: Lijun Ma, M.D., Ph.D. |
R01 DK087914(NIH)
06/21/2010-04/30/2015
Genetic Determinants of Adiposity in African Americans This study is focused on identifying genes that contribute to adiposity in the African American population. Principal Investigator: Maggie Ng, Ph.D.
Co-Investigator: Barry Freedman, M.D. |
Michael Rocco, MD |
HHSN268200900048C (NIH/NHLBI)
09/2009 – 09/2018
Systolic Blood Pressure Intervention Trial (SPRINT) The overall goal of the Systolic Blood Pressure Intervention Trial (SPRINT) is to conduct a multicenter, randomized, controlled clinical trial to determine whether treating SBP to a lower goal than currently recommended will reduce CVD. Prinicipal Investigator for Southeast Clinical Center Network: Michael Rocco, M.D.
Co-investigator for Southeast Clinical Center Network: Amret Hawfield, M.D. |
1UO1 DK066579 (NIH/NIDDK, Subcontract with RRI Institute)
05/2006 – 01/2013
Frequent Hemodialysis Clinical Trial (Daily HD) This randomized trial is designed to determine if short "daily" hemodialysis (six times per week) will decrease LV mass and improve quality of life compared to patients receiving standard three times per week hemodialysis. Principal Investigator for Clinical Center at Wake Forest School of Medicine: Michael Rocco, M.D. |
U01 DK6648 (NIH/NIDDK)
09/2003 – 01/2013
Frequent Hemodialysis Trials, Nocturnal Hemodialysis Clinical Coordinating Center This randomized trial is designed to determine if long "daily" nocturnal home hemodialysis (six times per week) will decrease LV mass and improve quality of life compared to patients receiving standard three times per week hemodialysis. Principal Investigator for Nocturnal Core Consortium: Michael Rocco, M.D. |
Lilly
09/2011—08/2013
A Randomized, Double-Masked, Placebo-Controlled, Mutlicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes Principal Investigator: Michael Rocco, M.D.
Co-Investigator: Mariana Murea, M.D. |
John Burkart, MD |
NxStage Medical, Inc.
11/2008—11/2013
FREEDOM Study—Following Rehabilitation, Economics and Everyday Dialysis Outcome Measurements Study Principal Investigator: John Burkart, M.D. |
Anthony Bleyer, MD, MS |
Pilanthropic
7/2007-6/2013 (annually renewed)
Medullary Cystic Kidney Disease The purpose of this study is to identify the genetic cause of medullary cystic kidney disease type 1 and to perform further characterization of medullary cystic kidney disease type 1 and type 2. Principal Investigator: Anthony J. Bleyer, M.D., M.S |
Anita Saran, MD |
Arbor Research Collaborative for Health
12/2010-11/2015
DOPPS—Dialysis Outcomes and Practice Patterns Study Principal Investigator: Anita Saran, M.D. |
Isai Bowline, MD |
Keryx Biopharmaceuticals, Inc.
6/2011—7/2014
A Long-Term Safety Extension Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) on Dialysis Principal Investigator: Isai Bowline, M.D. |